Everything drug pricing and policy, every day
And BIO is all about AI and China, but that’s not what’s catching my eye
Plus a Launch Price Comms Report, a handful of high-context research papers, and an op-ed focused on an under-the-radar IRA fix
Plus a guide to BIO convention sessions worth checking out, some 340B numbers, and my attempt to ignore MFN
And introducing the Cost Curve referral program, a way for me to thank you for introducing the newsletter to your friends and colleagues
And J&J launches its Center for U.S. Healthcare Policy Research
And Sandoz’s web page for its new biosimilar, Jubbonti, has a “value” section that breaks new ground
And IQVIA is out with its annual assessment of 340B: The program is huge and getting big fast
Including how experts see access in the IRA era, the most controversial “2028” IRA meds, and a roundup on the lawsuits
Including a review of this week’s ASCO meeting and the three best visualizations from IQVIA’s oncology report
